This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Recent studies have revealed that many UK families are unable to engage in today's digital society due to a lack of online skills and access to devices, data, and broadband. While this may seem ...

A digital version of the NHS Health Check offered to older people in the UK will be piloted in some areas of England early next year, according to the government. The Department of Health and ...

Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

J&J's high expectations for Rybrevant are driven mainly by its August approval with Lazcluze, which outperformed Tagrisso in ...

The challenge persists, but, with a renewed focus from regulatory bodies and trial sponsors alike on improving enrolment ...

Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping ...

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring ...

Novartis is putting $20 million upfront into a near-$1 billion deal with US start-up Lindy Biosciences that aims to convert biologic drugs delivered by infusion into therapies that can be self ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Fresh from reporting encouraging results with its oral weight-loss drug, Terns Pharma has moved swiftly ahead with a public offering, seeking to raise upwards of $125 million to fund additional ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).